OverviewSuggest Edit

Intra-Cellular Therapies is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). The Company develops compounds that have the potential to treat a wide range of diseases associated with the central nervous system. Intra-Cellular Therapies is developing its lead drug candidate, lumateperone, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders.

TypePublic
Founded2002
HQNew York, NY, US
Websiteintracellulartherapies.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Feb 2020)330(+353%)
Revenue (FY, 2020)$22.8 M(+37538%)
Share Price (Sept 2021)$38(+3%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Intra-Cellular Therapies

Sharon Mates

Sharon Mates

Founder, Chairman & Chief Executive Officer
Mark Neumann

Mark Neumann

Executive Vice President, Chief Commercial Officer
Richard Lerner

Richard Lerner

Director
Christopher Alafi

Christopher Alafi

Director
Michael Halstead

Michael Halstead

Senior Vice President and General Counsel
Michael I. Halstead

Michael I. Halstead

Executive Vice President and General Counsel
Show more

Intra-Cellular Therapies Office Locations

Intra-Cellular Therapies has an office in New York
New York, NY, US (HQ)
430 E 29th St #900
Show all (1)

Intra-Cellular Therapies Financials and Metrics

Intra-Cellular Therapies Revenue

Intra-Cellular Therapies's revenue was reported to be $22.81 m in FY, 2020
USD

Revenue (FY, 2020)

22.8m

Net income (FY, 2020)

(227.0m)

EBIT (FY, 2020)

(231.2m)

Market capitalization (23-Sept-2021)

3.0b

Closing stock price (23-Sept-2021)

38.0

Cash (31-Dec-2020)

60.0m

EV

3.0b
Intra-Cellular Therapies's current market capitalization is $3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

2.7m577.3k91.4k330.7k245.8k60.6k22.8m

Revenue growth, %

(79%)(84%)262%

General and administrative expense

6.0m10.3m18.2m24.8m23.7m30.1m64.9m186.4m

R&D expense

23.0m21.2m87.7m93.8m79.4m132.2m89.1m65.8m
Quarterly
USDQ1, 2014Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

668.0k167.8k219.2k124.4k3.3k57.4k228.4k4.4k95.3k114.7k30.8k1.1m1.9m

Cost of goods sold

69.0k

Gross profit

1.0m

Gross profit Margin, %

94%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

35.2m61.3m47.2m48.6m37.8m54.9m107.6m60.0m

Accounts Receivable

336.3k51.6k30.7k94.3k10.8m

Prepaid Expenses

762.2k1.3m8.0m4.9m7.9m6.3m14.2m

Inventories

4.0m7.1m
Quarterly
USDQ1, 2014Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

49.044.1m143.6m91.1m68.9m100.8m71.4m332.8m37.2m52.0m200.4m23.6m29.6m52.3m74.4m69.8m69.8m64.1m91.8m102.2m179.6m129.3m

Accounts Receivable

251.3k167.8k219.2k124.4k3.3k9.1k98.2k1.3k68.2k61.9k6.3k1.4m2.4m

Prepaid Expenses

806.3k585.1k493.4k1.4m1.3m8.6m1.5m6.8m4.0m4.0m3.8m6.1m5.3m6.1m5.9m7.3m8.3m3.0m4.0m7.9m4.7m

Inventories

1.4m2.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(26.9m)(30.7m)(104.8m)(116.4m)(97.8m)(155.1m)(147.7m)(227.0m)

Depreciation and Amortization

23.2k25.5k139.6k196.9k213.9k368.7k477.1k528.1k

Inventories

(7.1m)

Accounts Payable

3.4m(1.3m)(419.9k)2.1m2.4m7.8m(6.5m)(1.9m)
Show all financial metrics

Intra-Cellular Therapies Operating Metrics

FY, 2017

Patents and Patent Applications

80
Show all operating metrics

Intra-Cellular Therapies Revenue Breakdown

Embed Graph

Intra-Cellular Therapies revenue breakdown by business segment: 33.6% from License and collaboration revenue and 66.4% from Grant Revenue

Intra-Cellular Therapies Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Intra-Cellular Therapies Online and Social Media Presence

Embed Graph

Intra-Cellular Therapies Company Culture

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Intra-Cellular Therapies News and Updates

Intra-Cellular Therapies to Present at the 2021 Cantor Virtual Global Healthcare Conference

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and…

Intra-Cellular Therapies Announces Publications Highlighting Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Failure and in Models of Accelerated Aging

Results of Study ITI-214-104 show that lenrispodun, in a Phase 1/2a Study, is well tolerated and acts as an inodilator in patients with heart failure without inducing abnormal heart rhythms (Circulation: Heart Failure; Gilotra, et al, 2021)

Intra-Cellular Therapies to Present at the Canaccord Genuity 41st Annual Growth Conference

NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and …

Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update

CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021.

Intra-Cellular Therapies to Host Second Quarter 2021 Financial Results Conference Call and Webcast

NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast d…

Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update

CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression in adults as both monotherapy and adjunctive treatment with lithium or valproate have been accepted for review by the FDA, with a PDUFA target action date of December 17, 2021.
Show more

Intra-Cellular Therapies Blogs

Canaccord Genuity 41st Annual Growth Conference

Canaccord Genuity 41st Annual Growth Conference Matthew.Callan… Tue, 08/10/2021 - 08:26 Canaccord Genuity 41st Annual Growth Conference Display "add to calendar" true Event Type Corporate Conference Call Event Categories …

Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference

NEW YORK , Feb. 19, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and

Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference

Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference Content Import Tue, 01/05/2021 - 08:02 Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference January 5, 2021 at 8:00 AM EST This release…

Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast

Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast Content Import Wed, 11/04/2020 - 08:01 Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast November 4, 2020 at 8:00 AM EST …

Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference

Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference Content Import Tue, 08/06/2019 - 08:02 Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference Aug 6, 2019 This release is a backfill …

Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA

Agreement reached with FDA on submission of additional non-clinical information for NDA review of lumateperone for the treatment of schizophrenia Lumateperone PDUFA goal date extended three months to December 27, 2019 Conference call scheduled today at 8:30 am ET NEW YORK , Aug.
Show more

Intra-Cellular Therapies Frequently Asked Questions

  • When was Intra-Cellular Therapies founded?

    Intra-Cellular Therapies was founded in 2002.

  • Who are Intra-Cellular Therapies key executives?

    Intra-Cellular Therapies's key executives are Sharon Mates, Mark Neumann and Richard Lerner.

  • How many employees does Intra-Cellular Therapies have?

    Intra-Cellular Therapies has 330 employees.

  • What is Intra-Cellular Therapies revenue?

    Latest Intra-Cellular Therapies annual revenue is $22.8 m.

  • What is Intra-Cellular Therapies revenue per employee?

    Latest Intra-Cellular Therapies revenue per employee is $69.1 k.

  • Who are Intra-Cellular Therapies competitors?

    Competitors of Intra-Cellular Therapies include TRB Chemedica, Centurion and Repligen.

  • Where is Intra-Cellular Therapies headquarters?

    Intra-Cellular Therapies headquarters is located at 430 E 29th St #900, New York.

  • Where are Intra-Cellular Therapies offices?

    Intra-Cellular Therapies has an office in New York.

  • How many offices does Intra-Cellular Therapies have?

    Intra-Cellular Therapies has 1 office.